AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17038680 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine 210 mg total dose (15 mg/day)
Number of subjects: 210
Study 12707160 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% N(2)O
Number of subjects: 100
Study 12707160 — intervention group
Group type: COMPARATOR
Intervention: Control (0% N(2)O)
Number of subjects: 100
Study 12707160 — intervention group
Group type: EXPERIMENTAL
Intervention: N(2)O (all concentrations: 25%, 50%, 75%)
Number of subjects: 100
Study 10767583 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0
Study 10767583 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 9363045 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dosage abecarnil (3.0-7.0 mg daily)
Number of subjects: 182
Study 9363045 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage abecarnil (7.5-17.5 mg daily)
Number of subjects: 182
Study 9363045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 1491390 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine therapy
Number of subjects: 32
Study 1491390 — intervention group
Group type: COMPARATOR
Intervention: Control group (no remittive agents)
Number of subjects: 32
Study 4006379 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniphyl (two 400 mg tablets) under fasting conditions
Number of subjects: 18
Study 4006379 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur Sprinkle under nonfasting conditions
Number of subjects: 18
Study 31686742 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate (ISMN) 20 mg/day
Number of subjects: 100
Study 31686742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27669731 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Managing Anger Program (I-MAP), a Cognitive behavioural therapy (CBT) and mindfulness-based anger management intervention
Number of subjects: 24
Study 27669731 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 24
Study 28105463 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace flexibility/support intervention
Number of subjects: 396
Study 28105463 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 396
Study 23754275 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo condition (n = 15)
Number of subjects: 30
Study 23754275 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 15)
Number of subjects: 30
Study 23251579 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+
Number of subjects: 36
Study 23251579 — intervention group
Group type: EXPERIMENTAL
Intervention: HarmoKnee
Number of subjects: 36
Study 23251579 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 21180002 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleached with resin coating (group BC)
Number of subjects: 160
Study 21180002 — intervention group
Group type: COMPARATOR
Intervention: Bleached without resin coating (group B)
Number of subjects: 160
Study 21180002 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersed in artificial saliva with resin coating (group SC)
Number of subjects: 160
Study 21180002 — intervention group
Group type: COMPARATOR
Intervention: Immersed in artificial saliva without resin coating (group S)
Number of subjects: 160
Study 17714372 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 50
Study 17714372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15878467 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analyses of genetic associations
Number of subjects: 81
Study 15878467 — intervention group
Group type: COMPARATOR
Intervention: Meta-analyses of health care interventions
Number of subjects: 81
Study 11940031 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Therapy (FET) - 30 min daily sessions for 3 weeks
Number of subjects: 16
Study 11940031 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 11940031 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Therapy (FET) - LFG
Number of subjects: 16
Study 11940031 — intervention group
Group type: COMPARATOR
Intervention: Control group - LFG
Number of subjects: 16
Study 9616258 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological baroreflex sensitivity (sodium nitroprusside and phenylephrine)
Number of subjects: 20
Study 9616258 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous sequences of increasing and decreasing blood pressure and pulse interval
Number of subjects: 20
Study 9616258 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral analysis to derive alpha, the index of overall baroreflex gain
Number of subjects: 20
Study 9616258 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological methods
Number of subjects: 20
Study 9616258 — intervention group
Group type: COMPARATOR
Intervention: Spectral baroreflex sensitivity
Number of subjects: 20
Study 9616258 — intervention group
Group type: COMPARATOR
Intervention: Sequence methods
Number of subjects: 20
Study 8592993 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 100 mg
Number of subjects: 13
Study 8592993 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 200 mg
Number of subjects: 13
Study 8592993 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 400 mg
Number of subjects: 13
Study 8592993 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 600 mg
Number of subjects: 13
Study 8592993 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of 300 mg twice daily for 6.5 days
Number of subjects: 13
Study 8592993 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration of probenecid
Number of subjects: 13
Study 2913960 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methotrexate 0.1%
Number of subjects: 42
Study 2913960 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methotrexate 0.5%
Number of subjects: 42
Study 2913960 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methotrexate 1%
Number of subjects: 42
Study 2913960 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone (control)
Number of subjects: 42
Study 30742522 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% urea cream
Number of subjects: 41
Study 30742522 — intervention group
Group type: COMPARATOR
Intervention: sorbolene
Number of subjects: 41
Study 30742522 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both treatments
Number of subjects: 41
Study 26381118 — intervention group
Group type: EXPERIMENTAL
Intervention: Banded RME
Number of subjects: 42
Study 26381118 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic splint RME
Number of subjects: 42
Study 26381118 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified acrylic splint RME
Number of subjects: 42
Study 25002178 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (bolus 0.75 mg/kg; infusion 1.75 mg/kg per hour)
Number of subjects: 1812
Study 25002178 — intervention group
Group type: COMPARATOR
Intervention: Heparin (70 U/kg)
Number of subjects: 1812
Study 25002178 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 1812
Study 25002178 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1812
Study 24351495 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care model
Number of subjects: 164
Study 24351495 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 164
Study 21609832 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation of an internal model
Number of subjects: 0
Study 21609832 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition of the newly adapted movement
Number of subjects: 0
Study 21609832 — intervention group
Group type: EXPERIMENTAL
Intervention: Operant reinforcement through association of the adapted movement with successful error reduction
Number of subjects: 0
Study 18469248 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric supplementation (55 mg oxalate/d for 4 weeks)
Number of subjects: 11
Study 18469248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon supplementation (55 mg oxalate/d for 4 weeks)
Number of subjects: 11
Study 18469248 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (water only)
Number of subjects: 11
Study 18469248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon and turmeric supplementation
Number of subjects: 11
Study 16531835 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Symptom Validity Test (MSVT) administered to IME patients
Number of subjects: 0
Study 16531835 — intervention group
Group type: COMPARATOR
Intervention: Volunteers trying their best on the MSVT
Number of subjects: 0
Study 16531835 — intervention group
Group type: COMPARATOR
Intervention: Volunteers simulating memory impairment on the MSVT
Number of subjects: 0
Study 14646679 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 441
Study 14646679 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 441
Study 11140554 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing triclosan/copolymer (Colgate Total)
Number of subjects: 39
Study 11140554 — intervention group
Group type: COMPARATOR
Intervention: Control group used a dentifrice without triclosan/copolymer and interdental cleaning devices
Number of subjects: 39
Study 10437188 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Tong Jiang Oral Liquid with Da Huang (TJ)
Number of subjects: 0
Study 10437188 — intervention group
Group type: COMPARATOR
Intervention: Qi Yin Oral Liquid (QY)
Number of subjects: 0
Study 1441852 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrase thrombolysis
Number of subjects: 157
Study 1441852 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy plus heparin (control)
Number of subjects: 157
Study 2951807 — intervention group
Group type: EXPERIMENTAL
Intervention: Duovent (200 micrograms fenoterol + 40 micrograms ipratropium bromide)
Number of subjects: 26
Study 2951807 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (400 micrograms)
Number of subjects: 26
Study 2951807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms)
Number of subjects: 26
Study 2951807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 30027160 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal and/or written dietary advice (VWDA) in group A
Number of subjects: 75
Study 30027160 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal and/or written dietary advice (VWDA) in both groups
Number of subjects: 75
Study 30027160 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (VWDA) at T5
Number of subjects: 75
Study 26280588 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyaxial implants
Number of subjects: 59
Study 26280588 — intervention group
Group type: COMPARATOR
Intervention: Monoaxial dorsal fixators
Number of subjects: 59
Study 26280588 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminectomy
Number of subjects: 59
Study 26280588 — intervention group
Group type: COMPARATOR
Intervention: No laminectomy
Number of subjects: 59
Study 26280588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement-augmented screws in patients 60 years or older
Number of subjects: 59
Study 26280588 — intervention group
Group type: COMPARATOR
Intervention: Non-cement-augmented screws in patients 60 years or older
Number of subjects: 59
Study 26280588 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoaxial implant, cement-augmented, without laminectomy in patients 60 years or older
Number of subjects: 59
Study 24885354 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone before the first radiotherapy and three days placebo thereafter
Number of subjects: 411
Study 24885354 — intervention group
Group type: EXPERIMENTAL
Intervention: Four days 8 mg dexamethasone
Number of subjects: 411
Study 24885354 — intervention group
Group type: COMPARATOR
Intervention: Daily placebo for four days
Number of subjects: 411
Study 22280855 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI) TUR
Number of subjects: 148
Study 22280855 — intervention group
Group type: COMPARATOR
Intervention: White Light (WL) TUR
Number of subjects: 148
Study 20581392 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 433
Study 20581392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 433
Study 18343806 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir monotherapy
Number of subjects: 10
Study 18343806 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination (lopinavir/ritonavir + zidovudine + lamivudine)
Number of subjects: 10
Study 16542199 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 24
Study 16542199 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ibuprofen
Number of subjects: 24
Study 16542199 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 24
Study 16542199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12657404 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental sodium 5 mg/kg (Group 1)
Number of subjects: 60
Study 12657404 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg (Group 2)
Number of subjects: 60
Study 12657404 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg/kg (Group 3)
Number of subjects: 60
Study 11253341 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate mobilization and ambulation, external compression therapy, early Low Molecular Weight Heparin (LMWH) administration, and late oral anticoagulation.
Number of subjects: 0
Study 11253341 — intervention group
Group type: COMPARATOR
Intervention: Prolonged bed-rest
Number of subjects: 0
Study 9190049 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of names of former students
Number of subjects: 1
Study 9190049 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention interval
Number of subjects: 1
Study 1286052 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (0.05%, 0.5%, 1%, and 2%)
Number of subjects: 8
Study 1286052 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine (0.05%, 0.5%, 1%, and 2%)
Number of subjects: 8
Study 1286052 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.025%, 0.25%, 0.5%, and 0.75%)
Number of subjects: 8
Study 1286052 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 1286052 — intervention group
Group type: COMPARATOR
Intervention: Needle stick (no injection)
Number of subjects: 8
Study 1286052 — intervention group
Group type: COMPARATOR
Intervention: Saline with epinephrine (5 micrograms/ml)
Number of subjects: 8
Study 3084954 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol infusion (0.2‐2.0 micrograms/kg/min in Saline)
Number of subjects: 20
Study 3084954 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol inhalation (75 micrograms/kg in 2 ml Saline every two hours)
Number of subjects: 20
Study 3084954 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol infusion (2.0 micrograms/kg/min)
Number of subjects: 20
Study 30125462 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with reduced tacrolimus (EVR/rTAC) and steroid elimination
Number of subjects: 106
Study 30125462 — intervention group
Group type: COMPARATOR
Intervention: Standard tacrolimus with mycophenolate mofetil (sTAC/MMF) and steroids
Number of subjects: 106
Study 30125462 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with reduced tacrolimus (EVR/rTAC)
Number of subjects: 106
Study 30125462 — intervention group
Group type: COMPARATOR
Intervention: Standard tacrolimus with mycophenolate mofetil (sTAC/MMF)
Number of subjects: 106
Study 27797674 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein with 66 mg of isoflavones (SPI)
Number of subjects: 200
Study 27797674 — intervention group
Group type: COMPARATOR
Intervention: Soy protein alone without isoflavones (SP)
Number of subjects: 200
Study 26001289 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (LEN) treatment
Number of subjects: 13
Study 23558738 — intervention group
Group type: EXPERIMENTAL
Intervention: Temoporfin PDT (T‐PDT) plus stenting
Number of subjects: 11
Study 23558738 — intervention group
Group type: EXPERIMENTAL
Intervention: Temoporfin PDT (T‐PDT)
Number of subjects: 11
Study 21646584 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching focused on asthma home management and outpatient asthma monitoring visits (intervention group)
Number of subjects: 241
Study 21646584 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 241
Study 19194127 — intervention group
Group type: COMPARATOR
Intervention: Conventional carboplatin plus etoposide (CE) - carboplatin AUC 5 on day 1 IV and etoposide 140 mg/m IV on days 1-3, q28 days
Number of subjects: 79
Study 19194127 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-intensified carboplatin plus etoposide plus lenograstim - carboplatin AUC 5 on day 1 IV and etoposide 190 mg/m days 1-3 IV with lenograstim 263 microg subcutaneously on days 4-13, q21 days
Number of subjects: 79
Study 17047930 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Number of subjects: 145
Study 17047930 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 145
Study 15012621 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone plus finasteride (100 mg/day + 5 mg/day)
Number of subjects: 65
Study 15012621 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone (100 mg/day) alone
Number of subjects: 65
Study 11879339 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy (400 mg CBZ per day)
Number of subjects: 130
Study 11879339 — intervention group
Group type: COMPARATOR
Intervention: Polytherapy (200 mg CBZ plus 300 mg VPA per day)
Number of subjects: 130
Study 11879339 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 130
Study 11879339 — intervention group
Group type: COMPARATOR
Intervention: Polytherapy
Number of subjects: 130
Study 9324482 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 0
Study 8334827 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (1 mg kg‐1)
Number of subjects: 14
Study 8334827 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (1.5 mg kg‐1)
Number of subjects: 14
Study 8334827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3595669 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A: procarbazine (100 mg/m2 p.o., max 150 mg) days 1-10, vindesine (3 mg/m2 i.v., max 5 mg) days 1 and 8, CCNU (150 mg/m2 p.o., max 200 mg) day 1
Number of subjects: 43
Study 3595669 — intervention group
Group type: COMPARATOR
Intervention: Regimen B: procarbazine (100 mg/m2 p.o., max 150 mg) days 1-10, DTIC (250 mg/m2 i.v. max 400 mg) days 1-5, CCNU (150 mg/m2 p.o. max 200 mg) day 1
Number of subjects: 43
Study 31579919 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary surgery for unilateral cleft lip and palate
Number of subjects: 425
Study 30232866 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermosensitive moxibustion (TSM), applied to bilateral Taichong (LR 3) and Qiuxu (GB 40) once daily for 15 days.
Number of subjects: 60
Study 30232866 — intervention group
Group type: COMPARATOR
Intervention: Medication group (Estazolam tablets, 1 mg/d, once daily for 15 days).
Number of subjects: 60
Study 27058964 — intervention group
Group type: EXPERIMENTAL
Intervention: Single HA injection
Number of subjects: 51
Study 27058964 — intervention group
Group type: EXPERIMENTAL
Intervention: Double HA injection
Number of subjects: 51
Study 27058964 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization splint therapy
Number of subjects: 51
Study 27058964 — intervention group
Group type: COMPARATOR
Intervention: Control group (self-selected)
Number of subjects: 51
Study 24704800 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro‐Self(©) Plus Pain Control Program
Number of subjects: 0
Study 22846453 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance exercise
Number of subjects: 28
Study 22846453 — intervention group
Group type: COMPARATOR
Intervention: Standard care control (encouragement to exercise only)
Number of subjects: 28
Study 20932576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative risk index comprised of seven risk indicators
Number of subjects: 252
Study 20932576 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental increase in cumulative risk
Number of subjects: 252
Study 18625670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosimeter method
Number of subjects: 27
Study 16141746 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 3 weeks
Number of subjects: 44
Study 16141746 — intervention group
Group type: COMPARATOR
Intervention: Minimal activity control program
Number of subjects: 44
Study 11994561 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced prostate cancer patients (androgen ablated)
Number of subjects: 30
Study 11994561 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly males (mean age, 77 years)
Number of subjects: 30
Study 11994561 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched controls
Number of subjects: 30
Study 10026684 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway (92 patients)
Number of subjects: 163
Study 10026684 — intervention group
Group type: COMPARATOR
Intervention: Control group (71 patients)
Number of subjects: 163
Study 7593728 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300-600 mg daily)
Number of subjects: 70
Study 7593728 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20-40 mg daily)
Number of subjects: 70
Study 7593728 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 70
Study 7593728 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide and Fluoxetine
Number of subjects: 70
Study 2344514 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination by a urologist or general practitioner
Number of subjects: 1494
Study 7026542 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine (mean 81 mg/day)
Number of subjects: 43
Study 7026542 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (mean 144 mg/day)
Number of subjects: 43